AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35362862
Drug: Non-LEP treatment
RxNorm normalized name: rabies virus vaccine flury-lep strain Injection [RabAvert]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-LEP treatment (NSAIDs or Chinese herbal medicines)
Trial: 35362878
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (4 capsules of 530 mg EPA, 150 mg DHA)
Trial: 35363252
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion after bariatric surgery
Trial: 35364421
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles
Trial: 35364569
Drug: LCTOPC1 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCTOPC1 (2 × 10^6 cells) administered via intraparenchymal injection
Trial: 35366263
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nutraceuticals for 6 months as part of a Mediterranean diet
Trial: 35366312
Drug: Iron deficiency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron deficiency treatment
Trial: 35366312
Drug: Vitamin deficiency
RxNorm normalized name: Vitamin Deficiency Injectable System - B12 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin deficiency treatment
Trial: 35366613
Drug: Standard 'next-step'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 'next-step' treatment strategies
Trial: 35366711
Drug: Elevated blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated blood hemoglobin (HGB > 149.5 g/L)
Trial: 35366711
Drug: Normal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal blood hemoglobin (HGB ≤ 149.5 g/L)
Trial: 35366805
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment for HBV (20.3% of patients received this treatment)
Trial: 35366825
Drug: Preoperative accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative accelerated partial breast irradiation (APBI) using CyberKnife, single fraction (exact dosage not specified)
Trial: 35366963
Drug: Odronextamab (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odronextamab (up to 320 mg once per week, with maintenance every 2 weeks after cycle 4)
Trial: 35366963
Drug: Odronextamab (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odronextamab (doses of 5 mg or higher)
Trial: 35366963
Drug: Odronextamab (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odronextamab (doses of 80 mg or higher)
Trial: 35367396
Drug: iNKT cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNKT cell and PD-1+CD8+ T cell-based immunotherapy, infused every 3-5 weeks, considered 1 cycle.
Trial: 35367396
Drug: iNKT cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNKT cell and PD-1+CD8+ T cell-based immunotherapy
Trial: 35367616
Drug: Fluorescence guided
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescence guided photodynamic therapy (PDT) using a portable fibre-coupled LED system
Trial: 35367616
Drug: Fluorescence guided
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescence guided photodynamic therapy (PDT)
Trial: 35367851
Drug: Automatic dose
RxNorm normalized name: AMMONIA,AROMATIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic dose verification system with propagated contours
Trial: 35367908
Drug: Cancer screening,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer screening, risk reduction, and treatment
Trial: 35368221
Drug: 1.5% ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% ruxolitinib cream applied twice daily for 28 days, then continued on active lesions for an additional 28 days (extension period).
Trial: 39546129
Drug: 1.5% ruxolitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% ruxolitinib cream
Trial: 35369018
Drug: p-inulin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-inulin (8 g twice daily for 12 weeks)
Trial: 35369018
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (pretreatment phase)
Trial: 35369374
Drug: Medications containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications containing acid salts (Metformin hydrochloride at 2550 mg/d and Gabapentin hydrochloride at 2700 mg/d)
Trial: 35369374
Drug: Metformin hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride (15.4 meq/d)
Trial: 35369607
Drug: Ramucirumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (10 mg/kg) plus Gefitinib (250 mg/d)
Trial: 35369854
Drug: Inactivated SARS-CoV-2
RxNorm normalized name: Inactivated SARS-Cov-2 Vaccine
DrugBank: Inactivated SARS-CoV-2 Vaccine (Chinese Academy of Medical Sciences) (DB15863)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated SARS-CoV-2 vaccines
Trial: 35371427
Drug: Hetrombopag (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hetrombopag (7.5 mg once daily to a maximum of 15 mg once daily for 52 weeks)
Trial: 35373040
Drug: Lawton Instrumental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lawton Instrumental Activities of Daily Living (IADL)
Trial: 35373105
Drug: COVID-19 mRNA
RxNorm normalized name: COVID-19 mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 mRNA vaccines (BNT162b2 [BioNTech/Pfizer] or mRNA-1273 [Moderna])
Trial: 35373299
Drug: ADXS31-142 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADXS31-142 monotherapy (n = 13)
Trial: 35377133
Drug: Piperacillin-tazobactam 12/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam 12/1.5 g/24 h as a continuous infusion
Trial: 35377133
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose of 12/1.5 g/24 h
Trial: 35377133
Drug: Dosing guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing guided by renal function and therapeutic drug monitoring
Trial: 35378750
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Summer Camp and Parent Intervention (SCV + PI)
Trial: 35378952
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg BID on the first day, then 400 mg OD for a total of seven days
Trial: 35379237
Drug: Selinexor 80
RxNorm normalized name: SELINEXOR 80MG WEEKLY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 80 mg combined with low-dose dexamethasone (20 mg) administered orally on day 1 and day 3 of each week in 4-week cycles
Trial: 35379237
Drug: Selinexor 80
RxNorm normalized name: SELINEXOR 80MG WEEKLY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 80 mg combined with low-dose dexamethasone (20 mg)
Trial: 35379611
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibody in arm A (obvious response to TKIs)
Trial: 35379611
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) in arm B (general response to TKIs)
Trial: 35379611
Drug: Tyrosine kinase
RxNorm normalized name: Protein-tyrosine kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine kinase inhibitors (TKIs) in arm C (poor response to TKIs)
Trial: 35379630
Drug: Weekly text
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly text messages with three short questions assessing mood, worry, and pain (n=1851 subgroup)
Trial: 35379737
Drug: camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab plus apatinib (3 cycles of neoadjuvant therapy including three doses for 21 days)
Trial: 35379737
Drug: camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab plus apatinib (neoadjuvant therapy followed by surgery)
Trial: 35379737
Drug: camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab plus apatinib (adjuvant therapy after surgery)
Trial: 35379737
Drug: camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: camrelizumab plus apatinib (ctDNA status after adjuvant therapy)
Trial: 35379815
Drug: BBIBP-CorV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBIBP-CorV vaccine
Trial: 35379845
Drug: Antifolate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antifolate therapy
Trial: 35379979
Drug: Intravitreal sepofarsen
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal sepofarsen 160 µg/80 µg
Trial: 35379979
Drug: Intravitreal sepofarsen
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal sepofarsen 320 µg/160 µg
Trial: 35380627
Drug: Eating breakfast
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eating breakfast daily
Trial: 35382436
Drug: sMRI-guided radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sMRI-guided radiation therapy (RT) dose escalation to 75 Gy
Trial: 35382436
Drug: sMRI-guided RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sMRI-guided RT dose escalation to 75 Gy
Trial: 35383069
Drug: Computerised-decision support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised-decision support system (CDSS) for antibiotic stewardship (APSS) and electronic surveillance software (ESS) for infection surveillance (ZINC)
Trial: 35383088
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health intervention with 2 weekly text messages for 3 months after CR completion.
Trial: 35383117
Drug: Abatacept (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (60 mg/kg in three doses of 20 mg/kg each within the first 10 days, followed by two doses) combined with ruxolitinib and methylprednisolone
Trial: 35383117
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and mycophenolate-mofetil (initial treatment before abatacept)
Trial: 35383374
Drug: Cefotaxime 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 150 mg/kg/day (interval 6-8 h)
Trial: 35383374
Drug: Cefotaxime 200
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 200 mg/kg/day (interval 6 h)
Trial: 35383374
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose followed by continuous infusion regimens
Trial: 35383885
Drug: Zanubrutinib 320
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 320 mg once daily (QD)
Trial: 35383885
Drug: Zanubrutinib 160
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib 160 mg twice daily (BID)
Trial: 35385466
Drug: Multisensory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory stimulation (MSS) and soft tissue therapy (STT) for 5 consecutive days
Trial: 35385480
Drug: Rivaroxaban initiated
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban initiated < 72 hours after reperfusion therapy
Trial: 35385480
Drug: Rivaroxaban initiated
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban initiated ≥ 72 hours after reperfusion therapy
Trial: 35385922
Drug: Nilotinib (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (initial dose 400 mg twice daily, later reduced to 300 mg twice daily)
Trial: 35385993
Drug: Tepotinib (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepotinib (oral MET kinase inhibitor)
Trial: 35386419
Drug: Vagal Nerve
RxNorm normalized name: gammaCore Vagal Nerve Stimulator for Headache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagal Nerve Stimulation (VNS) therapy
Trial: 35386419
Drug: Statistical model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statistical model for prediction of response to VNS therapy
Trial: 35386508
Drug: hs-CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP levels 1-3 mg/L
Trial: 35386508
Drug: hs-CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP levels >3-10 mg/L
Trial: 35386508
Drug: hs-CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP levels >10 mg/L
Trial: 35386508
Drug: hs-CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-CRP levels <1 mg/L
Trial: 35386606
Drug: Fluoxetine 90
RxNorm normalized name: fluoxetine 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 90 mg once weekly for 10 weeks (increased to 180 mg once weekly if inadequate response)
Trial: 35386606
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily for 2 weeks (initial tolerance assessment)
Trial: 35387414
Drug: Preoperative Stereotactic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Stereotactic Body Radiation Therapy (SBRT) - 35 to 40 Gy in 5 fractions every other day
Trial: 35387421
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation (60 Gy in 30 fractions for PET responders)
Trial: 35387421
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation (74 Gy in 30 fractions for nonresponders)
Trial: 35387421
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation
Trial: 35387589
Drug: Perturbed walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perturbed walking with a concurrent cognitive task
Trial: 35388003
Drug: Ramucirumab (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (an anti-VEGFR2 monoclonal antibody)
Trial: 35388792
Drug: Monodisciplinary inclusive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monodisciplinary inclusive work measures (treatment as usual)
Trial: 38017325
Drug: EMI-137 (0.13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMI-137 (0.13 mg/kg)
Trial: 35391576
Drug: Chemotherapy/immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/immunotherapy
Trial: 35393425
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m²)
Trial: 35394445
Drug: Tablet computer-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer-based remote patient monitoring system
Trial: 35395574
Drug: Nurses' pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurses' pain assessment before analgesic consumption
Trial: 35395574
Drug: Nurses' pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurses' pain assessment 1 hour after analgesic consumption
Trial: 35395574
Drug: Agreement between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agreement between children's and nurses' pain scores before analgesic consumption
Trial: 35395574
Drug: Agreement between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agreement between children's and nurses' pain scores 1 hour after analgesic consumption
Trial: 35395574
Drug: Agreement between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agreement between children's and parents' pain scores before analgesic consumption
Trial: 35395574
Drug: Agreement between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agreement between children's and parents' pain scores 1 hour after analgesic consumption
Trial: 35395680
Drug: Entrectinib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrectinib (oral, once-daily)
Trial: 35396138
Drug: PDR-/HDR-brachytherapy as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR-/HDR-brachytherapy as boost after external beam radiation therapy up to a total dose of 91-96 Gy (EQD2, α/β = 3 Gy)
Trial: 35396138
Drug: PDR-/HDR-brachytherapy with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDR-/HDR-brachytherapy with simultaneous integrated focal boost to intra-prostatic tumor lesions up to a total dose of 108-119 Gy (EQD2, α/β = 3 Gy)
Trial: 35396812
Drug: Talazoparib 250mcg
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib 250mcg daily with carboplatin AUC5-6 and paclitaxel 80 mg/m²
Trial: 35396812
Drug: Talazoparib 250mcg
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib 250mcg on a 3- or 7-day schedule with carboplatin AUC6 and paclitaxel 80 mg/m²
Trial: 35397434
Drug: Gatipotuzumab (1400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatipotuzumab (1400 mg every 2 weeks) combined with tomuzotuximab (1200 mg every 2 weeks)
Trial: 35401389
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training during chemotherapy
Trial: 35401389
Drug: First line
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line chemotherapy without exercise training
Trial: 39632341
Drug: LEM 5
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: LEM 5 mg
Trial: 35403786
Drug: Microneedling procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Microneedling procedures (4 monthly sessions)
Trial: 35404402
Drug: Adagrasib (MRTX849)
RxNorm normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adagrasib (MRTX849) 600 mg twice daily
Trial: 35404455
Drug: Human milk
RxNorm normalized name: HUMAN MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human milk (HM) insulin concentrations
Trial: 35404683
Drug: 21-gene expression
RxNorm normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET)
Trial: 35404683
Drug: Guiding systemic
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guiding systemic treatment by both RS and ET response
Trial: 35404977
Drug: Community-based cross-sectional
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Community-based cross-sectional study with self-reported survey and oral fluid testing for HIV antibodies.
Trial: 35405360
Drug: Crizotinib treatment
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib treatment with low PD-L1 expression (TPS < 50%)
Trial: 35405360
Drug: Crizotinib treatment
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib treatment with high PD-L1 expression (TPS ≥ 50%)
Trial: 35406491
Drug: Pre-chemotherapy CA27.29
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-chemotherapy CA27.29 assessment